Cystic Fibrosis
Conditions
Brief summary
To evaluate the effect of ciprofloxacin on the pharmacokinetics (PK) of ivacaftor and on the pharmacokinetics of VX-661 when administered in combination with ivacaftor
Interventions
Sponsors
Vertex Pharmaceuticals Incorporated
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Willing and able to comply with scheduled visits, treatment plan, study restrictions,laboratory tests, contraception guidelines, and other study procedures * Healthy subjects, as defined by no clinically relevant abnormalities identified by a detailed medical history and full physical examination, including blood pressure and heart rate measurement, standard 12-lead ECG, and clinical laboratory tests. * Body mass index (BMI) of 18.0 to 31.0 kg/m2, inclusive, and a total body weight \>50 kg * Female subjects of childbearing potential must have a negative serum pregnancy test at screening and at the Day -1 Visit.
Exclusion criteria
* History of any illness, clinical condition, or other factor that, in the opinion of the investigator or the subject's general practitioner, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject * Inability to swallow capsules, or inadequate venous access. * History of febrile illness within 5 days before the first study drug dose * A screen positive for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus 1 or 2 antibodies. * For female subjects: Pregnant or nursing subjects and female subjects of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol. For male subjects: Subject has a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 120 days after the last study drug dose. * Any condition possibly affecting drug absorption * Abnormal renal function at screening
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PK parameters of ivacaftor and metabolites following concomitant dosing with ciprofloxacin relative to ivacaftor administered alone | Day 7, Day 14 | PK Parameters - maximum observed plasma concentrations (Cmax) and area under the concentration versus time curve (AUC), |
| PK parameters of VX-661 and metabolites when dosed in combination with ivacaftor and concomitant ciprofloxacin relative to VX-661 administered in combination with ivacaftor | Day 10, Day 20 | PK parameters - maximum observed plasma concentrations (Cmax) and area under the concentration versus time curve (AUC), |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PK parameters of ivacaftor and metabolites when administered in combination with VX-661, with and without concomitant ciprofloxacin | Day 10, Day 20 | PK Parameters - maximum observed plasma concentrations (Cmax) and area under the concentration versus time curve (AUC), |
| Safety and tolerability, as assessed by adverse events (AEs), vital signs, ECGs and laboratory assessments | Day 1 through Day 21 (cohort 1) or Day 34 (cohort2) | — |
Outcome results
None listed